β-Lactamase inhibitor

Venatorx Pharmaceuticals Announces Positive Phase 1 Results for VNRX-7145

Retrieved on: 
Wednesday, July 28, 2021
Health, Science, Pharmaceutical, Research, Clinical trials, Chemical compounds, Organic compounds, Heterocyclic compounds, Beta-lactamase, Antibiotic, Beta-lactamase inhibitors, β-Lactamase inhibitor, Pharmacokinetics, Cefepime, VNRX-7145, Venatorx Pharmaceuticals, Inc., VNRX-7145, VENATORX PHARMACEUTICALS, INC.

Venatorx Pharmaceuticals today announced positive top line results for its Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial ( ClinicalTrials.gov NCT04243863 ) of VNRX-7145, a novel component of the investigational oral antibiotic combination product.

Key Points: 
  • Venatorx Pharmaceuticals today announced positive top line results for its Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial ( ClinicalTrials.gov NCT04243863 ) of VNRX-7145, a novel component of the investigational oral antibiotic combination product.
  • The Phase 1 study was a 2-part, first-in-human dose-ranging study to evaluate the safety and pharmacokinetics (PK) of escalating oral doses of VNRX-7145.
  • Venatorxs two lead antibacterial clinical-stage programs are intravenous (cefepime-taniborbactam) and oral (ceftibuten/VNRX-7145) broad-spectrum beta-lactam/beta-lactamase inhibitor combinations that are in Phase 3 and Phase 1, respectively.
  • In addition, Venatorx is in Phase 1 with its first antiviral compound (VNRX-9945), a Hepatitis B virus inhibitor.

Qpex Biopharma Initiates Phase 1 Study of ORAvance™ for Oral Treatment of Drug-Resistant Gram-Negative Bacterial Infections

Retrieved on: 
Wednesday, May 12, 2021
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Beta-lactam antibiotics, β-lactam antibiotic, β-Lactamase inhibitor, Beta-lactamase, Biomedical Advanced Research and Development Authority, Beta-lactamase inhibitors, Antibiotics, Biocides, Drugs, Infectious diseases, Penicillins

The World Health Organization (WHO) has also prioritized development of new treatments for these pathogens.

Key Points: 
  • The World Health Organization (WHO) has also prioritized development of new treatments for these pathogens.
  • Two of the products use QPX7728, an ultra-broad-spectrum beta-lactamase inhibitor that restores the potency of beta-lactam antibiotics in vitro and in vivo.
  • Qpex\xe2\x80\x99s current collaboration with BARDA is focused on advancing a portfolio of novel antibiotics, including the QPX7728-based products OMNIvance and ORAvance.
  • For more information, please visit www.qpexbio.com and follow us on Twitter and LinkedIn .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210512005284/en/\n'

Worldwide Antibiotics Industry to 2026 - Featuring Pfizer, Bayer and Novartis Among Others

Retrieved on: 
Tuesday, March 30, 2021
Health sciences, Articles, Health, Beta-lactam antibiotics, Evolutionary biology, Pharmaceuticals policy, Veterinary medicine, Antimicrobial resistance, Antibiotic, Beta-lactamase, β-Lactamase inhibitor, Drug resistance

The Global Antibiotics Market size is expected to reach $62.5 billion by 2026, rising at a market growth of 5.3% CAGR during the forecast period.

Key Points: 
  • The Global Antibiotics Market size is expected to reach $62.5 billion by 2026, rising at a market growth of 5.3% CAGR during the forecast period.
  • Presently, the demand for beta-lactam and beta-lactamase inhibitors class of antibiotics is more among healthcare providers.
  • The antibiotics market is growing owing to the increasing consumption of antibiotics in middle and lower-income countries, huge investments in R&D activities by pharmaceutical companies, and the increasing number of infectious diseases.
  • Although, the development of antibiotic resistance and the rising cost of drug approval hinder the growth of the antibiotic market.

Global Antibiotics Market (2020 to 2026) - by Action Mechanism, Drug Class and Region - ResearchAndMarkets.com

Retrieved on: 
Friday, March 26, 2021
Health, Pharmaceutical, Health sciences, Health, Articles, Beta-lactam antibiotics, Evolutionary biology, Pharmaceuticals policy, Veterinary medicine, Beta-lactamase inhibitors, Antimicrobial resistance, β-Lactamase inhibitor, Antibiotic, Beta-lactamase

The "Global Antibiotics Market By Action Mechanism, By Drug Class, By Region, Industry Analysis and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Antibiotics Market By Action Mechanism, By Drug Class, By Region, Industry Analysis and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com's offering.
  • The Global Antibiotics Market size is expected to reach $62.5 billion by 2026, rising at a market growth of 5.3% CAGR during the forecast period.
  • Presently, the demand for beta-lactam and beta-lactamase inhibitors class of antibiotics is more among healthcare providers.
  • Although, the development of antibiotic resistance and the rising cost of drug approval hinder the growth of the antibiotic market.

Qpex Biopharma Initiates Phase 1 Clinical Trial of QPX7728 for Drug-Resistant Bacterial Infections

Retrieved on: 
Thursday, December 3, 2020
Biotechnology, Pharmaceutical, General Health, Health, Infectious diseases, Hospitals, Clinical trials, Other Health, Chemical compounds, Organic compounds, β-Lactamase inhibitor, Chemistry, Beta-lactamase, Beta-lactamase inhibitors, Antibiotics, β-lactam antibiotic, Beta-lactam, Carboxylic acids, Drug resistance, Discovery and development of cephalosporins, QPX7728, Biomedical Advanced Research and Development Authority (BARDA) Partnership, Brii Biosciences Partnership, Antimicrobial Resistance (AMR), Qpex Biopharma

Today marks another important milestone for Qpex as we begin advancing three novel product candidates into clinical trials during the coming months, said Michael Dudley, Pharm.D., president and chief executive officer of Qpex Biopharma.

Key Points: 
  • Today marks another important milestone for Qpex as we begin advancing three novel product candidates into clinical trials during the coming months, said Michael Dudley, Pharm.D., president and chief executive officer of Qpex Biopharma.
  • We believe that QPX7728 has demonstrated a preclinical profile that exceeds that of recently marketed beta-lactamase inhibitors, as well as those in ongoing clinical trials.
  • Beta-lactamases are bacterial enzymes that destroy beta-lactam antibiotics and are the major mechanism of resistance to these drugs in gram-negative bacteria.
  • Qpex has a multi-product collaboration with Brii Biosciences for the development and commercialization of three of its products in greater China.

Antabio Receives QIDP Designation From the U.S. FDA for the Development of MEM-ANT3310, a Novel Broad-Spectrum Combination Therapy Targeting WHO's Priority Pathogens

Retrieved on: 
Wednesday, May 6, 2020
Drugs, Health, Medicine, Carbapenem antibiotics, Moraxellaceae, Bacterial diseases, Gram-negative bacteria, Meropenem, RTT, Acinetobacter baumannii, β-Lactamase inhibitor, Beta-lactamase

ANT3310 potentiates meropenem activity against CRAB in murine infection models and restores meropenem susceptibility in 95% of A. baumannii clinical isolates.

Key Points: 
  • ANT3310 potentiates meropenem activity against CRAB in murine infection models and restores meropenem susceptibility in 95% of A. baumannii clinical isolates.
  • This is Antabio's second program to receive QIDP status, following QIDP designation of its Metallo Beta-Lactamase Inhibitor ANT2681 for cUTI awarded in June 2019.
  • Antabio is a private biopharmaceutical company developing novel antibacterial resistance-breakers to treat drug resistant infections in areas of highest unmet medical need.
  • Antabio is developing a portfolio of three programs which address WHO critical priority pathogens, and which are eligible for QIDP and streamlined development:
    SBLi Program.

Antabio Receives QIDP Designation From the U.S. FDA for the Development of MEM-ANT3310, a Novel Broad-Spectrum Combination Therapy Targeting WHO's Priority Pathogens

Retrieved on: 
Wednesday, May 6, 2020
Drugs, Health, Medicine, Carbapenem antibiotics, Moraxellaceae, Bacterial diseases, Gram-negative bacteria, Meropenem, RTT, Acinetobacter baumannii, β-Lactamase inhibitor, Beta-lactamase

ANT3310 potentiates meropenem activity against CRAB in murine infection models and restores meropenem susceptibility in 95% of A. baumannii clinical isolates.

Key Points: 
  • ANT3310 potentiates meropenem activity against CRAB in murine infection models and restores meropenem susceptibility in 95% of A. baumannii clinical isolates.
  • This is Antabio's second program to receive QIDP status, following QIDP designation of its Metallo Beta-Lactamase Inhibitor ANT2681 for cUTI awarded in June 2019.
  • Antabio is a private biopharmaceutical company developing novel antibacterial resistance-breakers to treat drug resistant infections in areas of highest unmet medical need.
  • Antabio is developing a portfolio of three programs which address WHO critical priority pathogens, and which are eligible for QIDP and streamlined development:
    SBLi Program.

Entasis Therapeutics to Present at the 28th Annual Credit Suisse Healthcare Conference

Retrieved on: 
Tuesday, October 29, 2019
Medical specialties, Medicine, Branches of biology, Pathogenic bacteria, Moraxellaceae, Penicillins, Antibiotic, Drug resistance, Neisseria gonorrhoeae, Acinetobacter, Gram-negative bacteria, β-Lactamase inhibitor

Investors attending the conference who are interested in meeting with Company management should contact their Credit Suisse representatives.

Key Points: 
  • Investors attending the conference who are interested in meeting with Company management should contact their Credit Suisse representatives.
  • Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria.
  • Entasis pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targetingAcinetobacter baumanniiinfections), zoliflodacin (targetingNeisseria gonorrhoeae), and ETX0282CPDP (targetingEnterobacteriaceaeinfections).
  • Entasis is also using its platform to develop a novel class of antibiotics, non--lactam inhibitors of the penicillin-binding proteins (NBPs) (targeting Gram-negative infections).

Global Antibiotics Market Analysis, Trends, and Forecasts, Report 2019-2025: Overview, Focus On Select Players, Trends & Drivers, Market Perspective

Retrieved on: 
Friday, October 25, 2019
Beta-lactam antibiotics, Chemical compounds, Organic compounds, β-Lactamase inhibitor, Beta-lactamase inhibitors, Beta-lactamase, Heterocyclic compounds, Penicillins, Beta-lactam

DUBLIN, Oct. 25, 2019 /PRNewswire/ -- The "Antibiotics - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Oct. 25, 2019 /PRNewswire/ -- The "Antibiotics - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.
  • The shifting dynamics supporting this growth makes it critical for businesses in this space to keep abreast of the changing pulse of the market.
  • Poised to reach over US$20.5 Billion by the year 2025, Beta Lactam & Beta Lactamase Inhibitors will bring in healthy gains adding significant momentum to global growth.
  • In Japan, Beta Lactam & Beta Lactamase Inhibitors will reach a market size of US$1.2 Billion by the close of the analysis period.

Antibiotics Market Analysis, Trends, and Forecasts, 2025 - Worldwide Market is Projected to Grow by US$7.2 Billion - ResearchAndMarkets.com

Retrieved on: 
Friday, October 25, 2019
Health, Pharmaceutical, Beta-lactam antibiotics, Chemical compounds, Organic compounds, Beta-lactamase inhibitors, β-Lactamase inhibitor, Beta-lactamase, Penicillins, Heterocyclic compounds, Beta-lactam

The Antibiotics market worldwide is projected to grow by US$7.2 Billion, driven by a compounded growth of 2.3%

Key Points: 
  • The Antibiotics market worldwide is projected to grow by US$7.2 Billion, driven by a compounded growth of 2.3%
    Beta Lactam & Beta Lactamase Inhibitors, one of the segments analyzed and sized in this study, displays the potential to grow at over 2.7%.
  • The shifting dynamics supporting this growth makes it critical for businesses in this space to keep abreast of the changing pulse of the market.
  • Poised to reach over US$20.5 Billion by the year 2025, Beta Lactam & Beta Lactamase Inhibitors will bring in healthy gains adding significant momentum to global growth.
  • In Japan, Beta Lactam & Beta Lactamase Inhibitors will reach a market size of US$1.2 Billion by the close of the analysis period.